Editas Medicine (EDIT) Names New Chief Scientific Officer

August 22, 2016 8:23 AM EDT
Get Alerts EDIT Hot Sheet
Trade EDIT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the appointment of Charles Albright, Ph.D. as Chief Scientific Officer. Dr. Albright brings to Editas more than 25 years of life sciences industry and academic leadership experience, most recently serving as Vice President of Genetically Defined Diseases and Genomics at Bristol-Myers Squibb (BMS).

“Charlie has an impressive track record of translating exciting science into real medicines for patients in need,” said Katrine Bosley, President and Chief Executive Officer of Editas Medicine. “He has brought numerous new medicines from discovery into clinical development across many disease areas. During this period of significant growth at Editas, I am very pleased to welcome him to the team and look forward to his many contributions as we continue to build this organization for the long-term.”

“As a leader in the field, Editas is building an impressive and diversified pipeline focused on treating patients with a broad range of genetically defined diseases,” said Dr. Albright. “I am excited to join the dynamic team at Editas and to help pioneer this exciting wave of innovation around genomic medicines.”

Over his career, Dr. Albright has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain, psychiatry, oncology and inflammation. Prior to his position as Vice President of Genetically Defined Diseases and Genomics, he held multiple scientific leadership roles in Neuroscience Biology at BMS. Previously, he held positions at Incyte Corporation and DuPont Pharmaceuticals and was an Assistant Professor of Biochemistry at Vanderbilt University. Dr. Albright received a Bachelor of Science in Chemical Engineering and a Ph.D. in Biology from the Massachusetts Institute of Technology (MIT). He was a postdoctoral fellow in the laboratory of Professor Robert Weinberg at the Whitehead Institute for Biomedical Research at MIT.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Changes, Management Comments

Add Your Comment